Takeda Pharmaceutical Co Ltd
corporate_fare Company Profile
Takeda Pharmaceutical Co Ltd (NYSE:TAK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for TAK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-14, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for TAK spans 6-K, 144, 20-F.
Recent high-impact activity:
- FDA Grants Priority Review to Takeda's Zasocitinib for Plaque Psoriasis
- Takeda Secures FDA Approval for First-in-Class PV Therapy MIMRYLO
- Takeda Secures FDA Nod for First-in-Class Narcolepsy Therapy ORZEYFUL
- Takeda Q1 FY2026: Revenue Climbs 10% on Yen Weakness, Core Profit Flat; Full-Year Outlook Holds Steady
- Takeda Q1 Revenue +10.2% on Weak Yen; Pipeline Milestones on Track, FY Outlook Unchanged
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for TAK, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.
Share Issuance for LTIP · Significant Value
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
TAK files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.